Luísa Viterbo

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Hervé Avet‐Loiseau, Nizar J. Bahlis, Wee Joo Chng et al. · Blood · 2017 · 113 citations · Full text

Medicine, Hematology, Pharmacology +10

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial

Natacha Heutte, Hans‐Henning Flechtner, Nicolas Mounier et al. · The Lancet Oncology · 2009 · 103 citations

Medicine, Oncology, End-of-life Care +15

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

Heinz Ludwig, Luísa Viterbo, Richard Greil et al. · Journal of Clinical Oncology · 2012 · 82 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

María‐Victoria Mateos, Tamás Masszi, Norbert Grząśko et al. · Haematologica · 2017 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14